Literature DB >> 11749040

Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem.

A Wallén A1, D S Castro, R H Zetterström, M Karlén, L Olson, J Ericson, T Perlmann.   

Abstract

The orphan nuclear receptor Nurr1 is essential for development of midbrain dopamine (DA) cells. In Nurr1-deficient mice, DA precursor cells fail to migrate normally, are unable to innervate target areas, and only transiently express DA cell marker genes. In the search for Nurr1-regulated genes that might explain this developmental phenotype, we found that expression of the receptor tyrosine kinase Ret is deregulated in these cells of Nurr1-deficient embryos. In addition, our analyses establish Nurr1 as an early marker for the dorsal motor nucleus (DMN) of the vagus nerve. Interestingly, Ret expression is absent also in these cells in Nurr1-targeted mice. Neuronal innervation of vagus nerve target areas appeared normal apart from a subtle disorganization of the DMN-derived nerve fibers. In conclusion, regulation of Ret by Nurr1 in midbrain DA neurons and in the DMN has implications for both embryonal development and adult physiology in which signaling by neurotrophic factors plays important roles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11749040     DOI: 10.1006/mcne.2001.1057

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  35 in total

1.  Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons.

Authors:  Sangmi Chung; Kai-C Sonntag; Therese Andersson; Lars M Bjorklund; Jae-Joon Park; Dong-Wook Kim; Un Jung Kang; Ole Isacson; Kwang-Soo Kim
Journal:  Eur J Neurosci       Date:  2002-11       Impact factor: 3.386

2.  Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation.

Authors:  Kai-Christian Sonntag; Rabi Simantov; Kwang-Soo Kim; Ole Isacson
Journal:  Eur J Neurosci       Date:  2004-03       Impact factor: 3.386

3.  Nurr1 in Parkinson's disease and related disorders.

Authors:  Yaping Chu; Weidong Le; Katie Kompoliti; Joseph Jankovic; Elliott J Mufson; Jeffrey H Kordower
Journal:  J Comp Neurol       Date:  2006-01-20       Impact factor: 3.215

Review 4.  NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Authors:  Mickael Decressac; Nikolaos Volakakis; Anders Björklund; Thomas Perlmann
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 5.  Nuclear receptors in neural stem/progenitor cell homeostasis.

Authors:  Dimitrios Gkikas; Matina Tsampoula; Panagiotis K Politis
Journal:  Cell Mol Life Sci       Date:  2017-06-21       Impact factor: 9.261

Review 6.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

7.  Nato3 integrates with the Shh-Foxa2 transcriptional network regulating the differentiation of midbrain dopaminergic neurons.

Authors:  Einat Nissim-Eliraz; Sophie Zisman; Omri Schatz; Nissim Ben-Arie
Journal:  J Mol Neurosci       Date:  2012-12-21       Impact factor: 3.444

8.  Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.

Authors:  A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; D Suwelack; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2004-09       Impact factor: 11.454

9.  Brn3a and Nurr1 mediate a gene regulatory pathway for habenula development.

Authors:  Lely A Quina; Shirong Wang; Lydia Ng; Eric E Turner
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

10.  Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons.

Authors:  Dong-Youn Hwang; Sunghoi Hong; Joo-Won Jeong; Sangdun Choi; Hansoo Kim; Jangwoo Kim; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.